Skip to content

Towards Participatory Paediatric Asthma Action Plans

Towards Participatory Paediatric Asthma Action Plans

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04810169
Acronym
PACAP
Enrollment
120
Registered
2021-03-22
Start date
2021-12-10
Completion date
2023-07-26
Last updated
2025-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Keywords

Action plan, Asthma, Paediatric

Brief summary

Asthma is the most common chronic disease in children. The management of asthma attacks at home is based on asthma action plans that are very heterogeneous and reflect the diversity of recommendations on this subject. The purpose of this study is to observe using smartinhalers how children and their families use their emergency treatment at home in case of asthma symptoms and asthma attacks, to allow building new recommendations based not only on the literature, but also on real-world data.

Detailed description

Asthma is the most common chronic disease in children. Asthma exacerbations are responsible for many unscheduled consultations by paediatricians and general practitioners, numerous emergency room visits and frequent hospitalizations Asthma action plans are documents given to families and schools to give the actions to be taken in the event of an asthma attack occurring in the family or school environment. They are recommended by all learned societies, because, combined with patient education and regular consultations, they reduce the need for unscheduled care. The main drug in the action plan is the emergency treatment, i.e. a short-acting bronchodilator (SABA). However, the doses of SABA to be used vary widely depending on the recommendations. For children up to 5 years of age, the international board of the Global Initiative for Asthma (GINA) suggests limiting the home dose to 2 puffs of 100μg every 20 minutes, to be repeated twice before consulting a physician if there is no improvement. This dose is increased to 4-10 puffs every 20 minutes in children 6 years and older. The British Thoracic Society in the United Kingdom advises administering salbutamol puffs one at a time, 30 to 60 seconds apart, until symptoms improve, with a maximum of 10 puffs. In France, the Groupe de Recherche sur les Avancées en PneumoPédiatrie (GRAPP) recommends to administer higher doses of salbutamol at home, up to one puff per 2 kg of weight, with a maximum of 10 to 15 puffs, to be repeated every 20 minutes for one hour, before giving oral corticosteroids. These very heterogeneous protocols reflect the diversity of doses proposed in the literature, and the paucity of clinical research data that makes it impossible to determine whether one approach is better than another. A study that looked at the goals of parents of children with asthma highlighted that this heterogeneity of practices is a source of stress for families: I would like one plan and not ten explained one parent; I would like a plan that doesn't change all the time reported another. Harmonization of practices is necessary in order to provide families and school physicians nurses with a consistent approach.. The aim of this study is therefore to observe, using inhalers connected to salbutamol inhalers (smart inhalers), how families manage an asthma exacerbation at home, and to integrate these data into the establishment of future recommendations.

Interventions

DEVICESmart inhaler

* Automatic record (number of actuations and their timing) of the use of the emergency treatment through the smart inhaler * Questionnaire sent to the parents at each use of the smart inhaler to get information regarding the reason of use and the efficacy of the treatment given

Sponsors

URC-CIC Paris Descartes Necker Cochin
CollaboratorOTHER
Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
3 Years to 11 Years
Healthy volunteers
No

Inclusion criteria

* Parent of 18 years or more * Parent with a smartphone compatible with a smart inhaler * Parent with child who : * is 3 years to 11 years 11 months old * has physician-diagnosed asthma diagnosis * has a prescription of emergency treatment in case of asthma symptom * Non-opposition of the legal guardian

Exclusion criteria

* Refuse to participate at the study * Difficulty reading and/or understanding French language * Technical problem (malfunction) with the smart inhalers and/or the associated mobile application during the initial test with the parent's smartphone

Design outcomes

Primary

MeasureTime frameDescription
Mean number of emergency-treatments administered in the first two hours of management6 monthsMean number of emergency-treatments administered in the first two hours of management, depending on the symptoms initially presented by the child (cough, wheezing, dyspnea, or respiratory distress) or an association of symptoms, which led to the disappearance of the symptom(s) that prompted the initiation of salbutamol.

Secondary

MeasureTime frameDescription
Improvement of one or more symptoms6 monthsImprovement of the symptom(s), defined in a binary manner as an improvement reported by parents on the mobile application within 24 hours of the onset of the symptom(s).
Elimination of one or more symptoms6 monthsElimination of one or more symptoms defined in a binary manner (success/failure) by not using salbutamol for an asthmatic symptom within 24 hours of the onset of the symptom or symptoms.
Compliance score for action plan6 monthstaking into account the number of salbutamol puffs administered compared to the recommended number of salbutamol puffs, the duration between salbutamol puffs compared to the recommended duration, and the sequence of actions performed (including corticosteroids and use of the healthcare system) compared to the recommended sequence of actions - This score will be calculated as follows: (Number of expected actions on the action plan and according to the evolution of symptoms - Number of actions recorded by the smartinhalers and on the research application) / number of expected actions \* 100.
Overtreatment by families6 monthsFamily overuse of salbutamol, defined as ((number of puffs recorded - number of puffs expected)/(number of puffs expected) \* 100) strictly greater than 50%.
Undertreatment by families6 monthsUnder-use of salbutamol by families, defined as ((number of puffs recorded - number of puffs expected)/(number of puffs expected) \* 100) strictly less than -50%.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026